Fig. 3
From: A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia
Proportion of patients reaching ELN 2013 milestones of (a) optimal response and (b) DMR (MR4 or deeper) at indicated timepoints per initial TKI. Numbers above bars represent patients that achieved optimal response/DMR per total patients with available response data at the respective timepoint in that treatment group. DMR, deep molecular response; TKI, tyrosine kinase inhibitor